Purple Biotech Ltd Stock Price, News & Analysis

Purple Biotech (NASDAQ: PPBT) reported Q3 2025 results and a business update on Nov 14, 2025. Key financials: $10.5M cash and short-term deposits as of Sept 30, 2025, with an expected cash runway into the first half of 2027. Q3 operating loss was $1.4M and adjusted operating loss $1.3M. R&D expenses declined to $0.6M (56% decrease YoY) largely from reduced CM24 Phase 2 costs.

Clinical and pipeline highlights: IM1240 achieved a commercially viable manufacturing yield and is being advanced toward an IND and Phase 1 initiation in 2026. IM1305 was nominated as a second CAPTN-3 tri-specific candidate targeting TROP2. NT219 Phase 2 and CM24 biomarker-driven plans continue.

Purple Biotech (NASDAQ: PPBT) announced a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3 and NKG2A. The company reports achieving a commercially viable yield and high-purity process for IM1240, validating CAPTN-3's scalability for complex tri-specific antibodies. IM1240 includes a protease-cleavable, albumin-bound cap intended to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. The program is advancing toward first-in-human studies with an IND submission planned for 2026.

Purple Biotech (NASDAQ/TASE: PPBT) received a Nasdaq notice on Oct 16, 2025 that its American Depositary Shares closed below the required $1.00 minimum for 30 consecutive trading days. Under Nasdaq Listing Rule 5810(c)(3)(A) the company has a 180‑day cure period until April 14, 2026 to regain compliance by achieving a closing bid ≥ $1.00 for ten consecutive business days. The notice does not affect the current Nasdaq listing or trading of ADSs, nor its Tel Aviv listing. If noncompliant by April 14, 2026, Purple Biotech may be eligible for a second 180‑day period if it meets market‑value and other listing standards, or face delisting and the option to appeal. The company said it will monitor the ADS price and may consider options such as changing the ADS-to-ordinary share ratio to regain compliance.

Purple Biotech (NASDAQ/TASE: PPBT) has received an intention to grant from the European Patent Office for a patent application covering NT219 combinations with immunotherapies and MEK inhibitors. The patent (Application No. 20168234.1) will protect combinations of NT219 with various immunotherapies including anti-PD-1, PD-L1, CTLA-4, and CD20 antibodies, designed to enhance treatment of resistant cancers.

The company is currently conducting a Phase 2 study evaluating NT219 in combination with either pembrolizumab or cetuximab for squamous cell carcinoma of the head and neck (SCCHN). Preclinical studies have demonstrated synergistic activity of NT219 with immunotherapy in suppressing refractory tumors across multiple indications. The patent protection extends through 2036.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on oncology therapeutics, has closed its previously announced public offering. The offering includes 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, with each ADS representing 200 ordinary shares, at $1.00 per share.

The offering also includes short-term warrants to purchase up to 11,999,998 ADSs at an exercise price of $1.00 per ADS, exercisable immediately and expiring in 24 months. The initial gross proceeds total $6 million, with potential additional proceeds of $12 million if all warrants are exercised. H.C. Wainwright & Co. served as the exclusive placement agent.

The company plans to use the proceeds for developing its oncology therapeutic candidates and general working capital purposes.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the pricing of a $6 million public offering with potential additional proceeds of up to $12 million through warrant exercises.

The offering consists of 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, priced at $1.00 per share. Each ADS represents 200 ordinary shares. Additionally, short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per ADS will be issued, exercisable immediately and expiring in 24 months. The offering is expected to close around September 5, 2025.

H.C. Wainwright & Co. serves as the exclusive placement agent. Proceeds will fund oncology therapeutic candidates development and general corporate purposes.

Purple Biotech (NASDAQ/TASE: PPBT) has announced promising new data for its CAPTN-3 tri-specific antibody IM1240 in collaboration with Mount Sinai. The research, led by Dr. Amir Horowitz, demonstrated successful tumor cell death in treatment-resistant head and neck cancer biopsies.

Key findings show synergistic effects between NK and T cell engager arms of IM1240, and analysis of 26,000 human transcriptomes validates the antibody's design targeting 5T4 and NKG2A. The company plans to submit an IND application in 2026 for first-in-human clinical trials.

The research spans multiple resistant cancers including NSCLC, HNSCC, and bladder cancer. IM1240's unique design offers potentially safer checkpoint inhibition compared to existing therapies, particularly through its selective NKG2A targeting.

Purple Biotech (NASDAQ/TASE: PPBT) has announced the development of IM1305, its second CAPTN-3 tri-specific antibody targeting TROP2. The novel antibody combines a masked anti-CD3 arm, an anti-NKG2A arm, and an anti-TROP2 arm to target solid tumors.

Preclinical results show sustained tumor regression in human triple negative breast cancer (TNBC) mouse models, with significant cell death induction across multiple tumor types at low doses. The antibody's unique design includes a cleavable cap that activates specifically in the tumor microenvironment, potentially reducing off-target effects.

TROP2, the target protein, is widely expressed in major solid tumors including breast, lung, gastrointestinal, and ovarian cancers. The company plans to leverage its platform technology to accelerate development and explore partnering opportunities.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO Gil Efron will participate in a fireside chat on September 10, 2025, at 11:30 AM ET. The company will also be available for one-on-one investor meetings through the conference portal.